As reported in analystratings.com Linda Moussatos,PHD of Wedbush Securities maintained an Outperform rating on Sangamo Biosciences (NASDAQ: SGMO), with a price target of $30. The company’s shares opened Friday at $11.51.
"Moussatos commented, “Sangamo recently announced that it would shelve its current ZFN therapeutic strategy for β-thalassemia in favor for a new combined ZFN therapeutic approach for β-thalassemia and sickle cell disease. We understand that preclinical data (see summary of ASGCT Abstract 53 below) support the development of ZFN mediated deletion of Bcl11a enhancer for these programs. While there is a delay caused by dropping the Phase 1 ready Bcl11a gene knockout strategy for β-thalassemia, consolidation of the strategy used for β-thalassemia and sickle cell disease programs could provide benefits–including cost savings, a more direct read through for clinical efficacy and safety between the two indications, and a faster collective time for approval for both programs.”"
About Liana Moussatos:
Liana Moussatos joined Wedbush Securities as a managing director and senior research analyst from Pacific Growth Equities, where she was a senior research analyst. Previously, she was director and portfolio manager of the UBS Global Biotech Funds for five years at UBS Global Asset Management. Moussatos also was with Bristol-Meyers Squibb, where she was a manager in University and Government Licensing, External Science and Technology. She also worked with Sloan-Kettering Cancer Institute in the Office of Industrial Affairs, and with the National Cancer Institute in the Office of Technology Development. Moussatos received a bachelor's degree in entomology and a master's degree in zoology and biochemistry from Clemson University. She also earned a Ph.D. in plant pathology from the University of California, Davis, and completed a postdoctoral research fellowship in cellular and molecular physiology at the Yale School of Medicine
No comments:
Post a Comment